TY - JOUR
T1 - Cannabis Use Is Associated with Increased Risk of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
T2 - Analysis of the US Nationwide Inpatient Sample Database, 2004-2014
AU - Njei, Basile
AU - Sharma, Prabin
AU - McCarty, Thomas R.
AU - Singh, Manpreet
AU - Haque, Lamia
AU - Aslanian, Harry R.
AU - Jamidar, Priya
AU - Muniraj, Thiruvengadam
N1 - Funding Information:
The study sample originated from the US National Inpatient Sample (NIS) database, which includes hospitalized patients in the United States during the 2004 to 2014 period. This registry is part of the Healthcare Cost and Utilization Project, sponsored by the Agency for Healthcare Research and Quality.15 Each discharge is coded with a principal diagnosis for that specific hospitalization in addition to the potential for 14 secondary diagnoses and 15 associated procedures. Detailed information regarding the NIS database is highlighted in Supplemental Digital Content, Appendix 1 (http://links.lww.com/MPA/A675).
Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Objective The aim of this study was to investigate the impact of cannabis on post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP). Methods The US Nationwide Inpatient Sample was queried to identify patients who underwent endoscopic retrograde cholangiopancreatography pancreatitis from 2004 to 2014. Cannabis use was identified by International Classification of Diseases, Ninth Edition codes, and patients in remission were excluded. Poisson regression models were used to derive adjusted incidence risk ratios (IRRs) for outcomes. Results Among 37,712 patients with PEP, 0.4% had documented cannabis use disorder. From 2004 to 2014, the rate of PEP and cannabis use increased (8.9%-11.0% [P < 0.01] and 0.20%-0.70% [P < 0.01], respectively). Univariate analysis demonstrated cannabis was associated with increased risk of PEP (IRR, 1.70; 95% confidence interval [CI], 1.50-1.90; P < 0.01). On multivariate analysis, cannabis use was an independent predictor of PEP (IRR, 1.2; 95% CI, 1.1-1.4; P = 0.004). Cannabis was not associated with in-hospital death (IRR, 0.15; 95% CI, 0.02-1.04; P = 0.06) but was associated with shorter hospital stay (IRR, 0.96; 95% CI, 0.94-0.98; P < 0.001) and lower costs (IRR, 0.91; 95% CI, 0.91-0.92; P < 0.001). Conclusions Cannabis use was associated with an increase in PEP without significant increase in mortality.
AB - Objective The aim of this study was to investigate the impact of cannabis on post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP). Methods The US Nationwide Inpatient Sample was queried to identify patients who underwent endoscopic retrograde cholangiopancreatography pancreatitis from 2004 to 2014. Cannabis use was identified by International Classification of Diseases, Ninth Edition codes, and patients in remission were excluded. Poisson regression models were used to derive adjusted incidence risk ratios (IRRs) for outcomes. Results Among 37,712 patients with PEP, 0.4% had documented cannabis use disorder. From 2004 to 2014, the rate of PEP and cannabis use increased (8.9%-11.0% [P < 0.01] and 0.20%-0.70% [P < 0.01], respectively). Univariate analysis demonstrated cannabis was associated with increased risk of PEP (IRR, 1.70; 95% confidence interval [CI], 1.50-1.90; P < 0.01). On multivariate analysis, cannabis use was an independent predictor of PEP (IRR, 1.2; 95% CI, 1.1-1.4; P = 0.004). Cannabis was not associated with in-hospital death (IRR, 0.15; 95% CI, 0.02-1.04; P = 0.06) but was associated with shorter hospital stay (IRR, 0.96; 95% CI, 0.94-0.98; P < 0.001) and lower costs (IRR, 0.91; 95% CI, 0.91-0.92; P < 0.001). Conclusions Cannabis use was associated with an increase in PEP without significant increase in mortality.
UR - http://www.scopus.com/inward/record.url?scp=85053669142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053669142&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000001143
DO - 10.1097/MPA.0000000000001143
M3 - Article
C2 - 30134357
AN - SCOPUS:85053669142
SN - 0885-3177
VL - 47
SP - 1142
EP - 1149
JO - Pancreas
JF - Pancreas
IS - 9
ER -